

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2006 (31.08.2006)

PCT

(10) International Publication Number
WO 2006/090279 A1

(51) International Patent Classification:

C07D 405/14 (2006.01) **A61K 31/454** (2006.01)
C07D 401/14 (2006.01) **A61P 1/04** (2006.01)
C07D 401/12 (2006.01)

Development, Nagoya, Pfizer Japan Inc., 2, Aza 5-gochi,
Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP).

(21) International Application Number:

PCT/IB2006/000519

(22) International Filing Date:

10 February 2006 (10.02.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/655,276 22 February 2005 (22.02.2005) US

(71) Applicant (for JP only): **PFIZER JAPAN INC.** [JP/JP];
Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku,
Tokyo 151-8589 (JP).

(71) Applicant (for all designated States except JP, US):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KAWAMURA,**
Kiyoshi [JP/JP]; Pfizer Global Research and Devel-
opment, Nagoya, Pfizer Japan Inc., 2, Aza 5-gochi,
Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP).
SONE, Hiroki [JP/JP]; Pfizer Global Research and De-
velopment, Nagoya, Pfizer Japan Inc., 2, Aza 5-gochi,
Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP).
UCHIDA, Chikara [JP/JP]; Pfizer Global Research and

(74) Agent: **FULLER, Grover, Jr., F.**; c/o DROUIN,
Stéphane, Pfizer Research and Development, Ramsgate
Road, Kent, Sandwich CT13 9NJ (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: OXYINDOLE DERIVATIVES AS 5HT₄ RECEPTOR AGONISTS



(57) Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, R¹, R², R³, R⁴ and R⁵ are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT₄ agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes or apnea syndrome.